TapImmune Appoints Dr Robert Florkiewicz as Senior Director of Molecular Biology & Virology

April 11, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has announced that Robert Florkiewicz, Ph.D., has been appointed Senior Director of Molecular Biology & Virology. “Bob has a unique combination of skills and experience in the fields of virology and molecular biology that encompasses both the science and intellectual property landscapes” said Mark Reddish, Head…

Details

TapImmune Inc. to Present at BioPartnering North America. 10th Annual Event takes place in Vancouver British Columbia Feb 26-28 2012

February 27 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) a vaccine technologies company specializing in the development of innovative immunotherapeutics and vaccines in the areas of oncology and infectious disease, is pleased to announce that Dr. Glynn Wilson, Chief Executive Officer, will be presenting at the 10th Annual BioPartnering North America (BPN) in Vancouver, BC,…

Details

TapImmune to Open New Laboratories and Offices at 1551 Eastlake Ave. Comprehensive Lab Facilities Located in Seattle’s Newest Biotech Hub

January 18, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has signed a sub-lease for newly-renovated, state of the art laboratory and office space at 1551 Eastlake Avenue in South Lake Union — in the heart of Seattle’s vibrant biotech and medical community. The sublease was signed with Puget Sound Blood Center Research Institute and includes…

Details

TapImmune Appoints Mark Reddish to its Management Team as Vice President Product Development

Former executive at ID Biomedical and Biomira Inc brings broad experience and expertise in Cancer and Biodefense product development November 22, 2011, Seattle WA, TapImmune Inc. (OTCBB: TPIV), is pleased to announce that Mark Reddish has joined its Management Team as Vice President of Product Development. Mark was formerly Vice President of Product Development and…

Details

TapImmune Inc. Announces Issuance of US Patent

Patent with broad claims relates to Method of Enhancing an Immune Response by augmenting the levels of TAP Seattle, WA, October 27 , 2011 — TapImmune Inc. (OTCBB: TPIV) announced that the US Patent Office has issued Patent 7,994,146 entitled “Method of Enhancing an Immune Response”. The invention relates to a method of enhancing an…

Details

TapImmune Inc. Announces Issuance of US Patent

Patent with broad claims relates to Method of Enhancing an Immune Response by augmenting the levels of TAP Seattle, WA, October 27 , 2011 — TapImmune Inc. (OTCBB: TPIV) announced that the US Patent Office has issued Patent 7,994,146 entitled “Method of Enhancing an Immune Response”. The invention relates to a method of enhancing an…

Details

TapImmune to Present at BIT’s 2nd Annual World Congress on Immunodiseases and Therapy in Guangzhou, China, November 18, 2011

Analysis of data showing relationship between TAP levels, disease progression and therapeutic intervention to be discussed SEATTLE, WA TapImmune Inc. (OTCBB: TPIV), a biotechnology company developing immunotherapies, today announced that its Chairman and CEO, Dr. Glynn Wilson, is an invited speaker at BIT’s 2nd Annual World Congress on Immunodiseases and Therapy to be held in…

Details